24 studies found for:    ALZHEIMER DISEASE 12
Show Display Options
Rank Status Study
1 Completed A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Drug: Rivastigmine transdermal
2 Completed The Effect of Cognitive Function as Measured by Repeated Cognitive Measures After 12 Weeks Treatment With Donepezil
Condition: Alzheimer's Disease
Interventions: Drug: Donepezil;   Drug: Placebo to match Aricept
3 Active, not recruiting Escitalopram for the Treatment of Depression in Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: escitalopram;   Drug: Placebo
4 Completed Proof of Concept Study of Cognitive Improvement in Patients With Alzheimer's Disease
Condition: Alzheimer Disease
Interventions: Drug: AZD3480;   Drug: Donepezil
5 Recruiting Memantine on Aggression and Agitation of Alzheimer's Disease (AD)
Condition: Alzheimer's Disease
Intervention: Drug: Memantine
6 Completed EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD)
Condition: Alzheimer's Disease
Intervention: Drug: Aricept
7 Withdrawn Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease
Condition: Severe Alzheimer's Disease
Intervention: Drug: Donepezil Hydrochloride (Aricept)
8 Completed Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease
Conditions: Alzheimer's Disease;   Dementia
Intervention: Drug: Donepezil hydrochloride
9 Completed Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.
Condition: Alzheimer Disease
Intervention: Drug: AVE1625
10 Recruiting Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
Conditions: Agitation Associated With;   Alzheimer's Disease;   Alzheimer's Type;   Mental Disorder;   Nervous System Diseases
Intervention: Drug: Brexpiprazole, OPC-34712
11 Recruiting A Study of Three Fixed-doses of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
Conditions: Agitation Associated With;   Alzheimer's Disease;   Alzheimer's Type;   Mental Disorder;   Nervous System Diseases
Intervention: Drug: Brexpiprazole, OPC-34712
12 Completed Study Evaluating the Safety, Tolerability and Efficacy of PBT2 in Patients With Early Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Drug: PBT2
13 Completed The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility
Condition: Mild to Severe Alzheimer's Disease
Intervention: Drug: Donepezil HCl
14 Completed Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment
Condition: Alzheimer's Disease
Intervention: Drug: Rivastigmine, memantine
15 Withdrawn AC-1204 Long-term Efficacy Response Trial (ALERT Protocol)
Condition: Alzheimer's Disease
Interventions: Drug: caprylic triglyceride;   Drug: long-chain triglyceride
16 Completed Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment
Condition: Alzheimer's Disease
Interventions: Drug: CHF 5074 1x;   Drug: CHF 5074 2x;   Drug: CHF 5074 3x;   Drug: Placebo
17 Completed Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)
Condition: Alzheimer's Disease
Interventions: Drug: CHF 5074 1x;   Drug: CHF 5074 2x;   Drug: CHF 5074 3x
18 Completed Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase
Condition: Alzheimer's Disease
Interventions: Drug: CHF 5074 1x;   Drug: CHF 5074 2x;   Drug: CHF 5074 3x
19 Unknown  Bupropion for the Treatment of Apathy in Alzheimer's Dementia
Condition: Apathy in Dementia
Interventions: Drug: Elontril;   Drug: placebo
20 Enrolling by invitation Effect of Cerefolin®/CerefolinNAC® on Biomarker Measurements
Conditions: Mild Cognitive Impairment;   Alzheimer's Disease;   Alzheimer's Disease Related Disorders
Intervention:

Previous Page Studies Shown (1-20) Next Page (21-24) Show next page of results
Indicates status has not been verified in more than two years